Page 6,919«..1020..6,9186,9196,9206,921..6,9306,940..»

New illegal drugs available in runup to Games

Posted: Published on April 21st, 2012

LONDON (Reuters) - During an informative and entertaining address to an anti-doping conference last month, German researcher Mario Thevis referred to "80, 90, 100" new performance-enhancing drugs for which no tests yet exist. "They act like EPO (erythropietin) but they are structurally different and that means the current EPO tests will not pick them up," he told delegates to the conference in London convened by worldsportslawreport. Thevis added that "according to anecdotal evidence and rumors" the drugs, which replicate EPO's blood-boosting qualities, were already used in elite sports. EPO stimulates the bone marrow to produce more red blood cells. This increases the oxygen-carrying capacity of the blood, allowing muscles to perform for longer. News that up to 100 new drugs could be available in the runup to this year's London Olympics will astonish only the naive. "It doesn't surprise me," responded World Anti-Doping Agency (WADA) director-general David Howman. "We are in the area where we are into third and fourth generations and they continue to climb. Whether they are detectable or not depends on the ability of the individual laboratory." One in two competitors will be tested during the London Games, including all medalists, and the estimated 400 daily tests … Continue reading

Posted in Drugs | Comments Off on New illegal drugs available in runup to Games

Pharmacy robbery suspect caught in chase

Posted: Published on April 21st, 2012

PEPPERELL -- Pepperell police units were dispatched to a robbery in progress around 6:50 p.m. Monday evening. Sgt. Nick Parker and Officers Jared Carruba and Stephen Mulkerin responded to the Pepperell Family Pharmacy at 74 Main St. Descriptions of a suspect threatening pharmacy staff with a hammer were relayed to the officers by Dispatcher Jeff Cormier. According to Police Chief David Scott, witnesses in the pharmacy and nearby area advised Officer Carruba that the lone suspect fled on foot and he was checking the area when he spotted the subject running and proceeded to pursue. "Officer Carrubba was smart getting out of his cruiser and speaking with people in the area while the other officers checked the area in their cruisers," Scott said. "Those of us who know Officer Carrubba know he had no problem keeping pace with the suspect on foot." Scott said Carrubba has been involved "in some high profile cases and always does a great job." Suspect Bryan Thorpe, 27, of 428 Main St. in Townsend, was apprehended after the short foot chase. He was charged with a subsequent offense of armed and masked robbery, larceny from a building, threat to commit a crime, larceny of a … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy robbery suspect caught in chase

Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty …

Posted: Published on April 21st, 2012

SAN FRANCISCO, April 20, 2012 /PRNewswire/ -- Health insurers should use both medical and pharmacy data to forecast specialty medication utilization and improve outcomes for members, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care Pharmacy (AMCP)'s 24th Annual Meeting & Expo in San Francisco. Pharmacy benefit managers (PBMs) have experienced a rapid rise in expensive specialty prescription drug use within the past few years. In 2011, specialty drugs comprised 0.5 percent of all claims but 15.2 percent of all prescription benefit expenditures across Prime's member network. In addition, the average specialty per-prescription cost was $2,637 in 2010 and total paid per capita increased 12.9 percent from 2010 ($10.24 to $11.36 per member per month). Previous studies have estimated that specialty medication drug spend could increase from 20 percent to 50 percent by 2030, highlighting the need for health insurers to better understand how to trend and forecast these costs due to rapid growth rate. "Specialty drugs offer life-saving treatment for patients with chronic illnesses, but they also carry a huge price tag, continuing to rise by double digits each year," said Patrick Gleason, PharmD, … Continue reading

Posted in Pharmacy | Comments Off on Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty …

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 …

Posted: Published on April 20th, 2012

SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus Associated Kinase 2) selective inhibitor that has demonstrated encouraging clinical benefit in phase 1 and 2 clinical studies in patients with primary myelofibrosis (MF) or MF secondary to other myeloproliferative neoplasms (MPN). Pacritinib has orphan drug designation in the U.S. and Europe for myelofibrosis. "JAK2 dysregulation is associated with a broad range of difficult-to-treat illnesses, including cancers and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today," said James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe a highly selective JAK2 inhibitor that also inhibits the JAK2 clonal mutation (JAK2V617F) offers a distinct biological and clinical advantage over marketed or development stage compounds which are non-selective inhibitors of the JAK pathway. We believe that the lack of suppression of red blood cell and platelet formation seen with pacritinib has the potential to satisfy a medical need not currently … Continue reading

Comments Off on Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 …

China medical tourism Cerebral Palsy stem cells therapy 9 clip – Video

Posted: Published on April 20th, 2012

18-04-2012 12:47 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web: or mail to us: Name: Garbo Bocskai Gender: Male Nationality: Hungary Age: 20 Start of treatment: 2007-08-30 Diagnosis: Cerebral palsy Treatment: Stem cell treatment Days admitted to the hospital: 50 Reason for coming to treatment: Garbo was born as a result of a premature birth after only 7.5 months of pregnancy, and he suffered Septicemia secondary to Gastroenteritis caused by Thrush only 13 days after birth. Once the infection had been resolved, the infant appeared to have inconsistent bilateral eye movements and paralysis of the lower limbs and was eventually diagnosed with a Brain Injury at the age of 6 months. His parents heard that here in Guangzhou, Gabor would receive the advanced stem cell treatment done by a very professional medical team. Read the original: China medical tourism Cerebral Palsy stem cells therapy 9 clip - Video … Continue reading

Comments Off on China medical tourism Cerebral Palsy stem cells therapy 9 clip – Video

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.

Posted: Published on April 20th, 2012

ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex:BTX) and its wholly owned subsidiary LifeMap Sciences today announced that they have signed a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The acquisition is expected to close within thirty days. XenneX holds the exclusive, worldwide licenses to market GeneCards and PanDaTox. GeneCards is a searchable, integrated, database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease related information, on all known and predicted human genes. GeneCards was developed by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel. PanDaTox is a recently developed, searchable, database that can be used to identify genes and intergenic regions that are unclonable in E. coli, to aid in the discovery of new antibiotics and biotechnologically beneficial functional genes, and to improve the efficiency of metabolic engineering. Since 2003, XenneX has been generating revenue from customers worldwide including biotechnology, pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property. GeneCards and PanDaTox are marketed by XenneX under a license from Yeda Research and Development Company Ltd, the Technology Transfer Company of the Weizmann Institute. Through the … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.

ACT Announces Third Dry AMD Patient Treated in Clinical Trial

Posted: Published on April 20th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The outpatient transplantation surgery was performed successfully, and the patient is recovering uneventfully. Gary Rabin, chairman and CEO of ACT, commented, The completion of enrollment of the first cohort of patients in our dry AMD clinical trial is a significant step forward in our RPE clinical program. The first six patients in the U.S. trials have all been treated at UCLA, and as we have recently announced, the trials should soon expand to additional sites. As we have built our clinical team, we have been fortunate to have attracted the attention of some of the highest-caliber ophthalmologists and related institutions in the U.S. and Europe and recognize the huge value that their expertise provides us as we plan for the future of our therapeutic programs. With their guidance, we have also worked with the FDA to successfully expand the criteria of eligibility for patients to participate in our dry … Continue reading

Posted in Stem Cell Human Trials | Comments Off on ACT Announces Third Dry AMD Patient Treated in Clinical Trial

New Stem Cell Found in the Brain

Posted: Published on April 20th, 2012

GRAND RAPIDS, Mich., April 19, 2012 /PRNewswire/ --Researchers at Lund University in Sweden have discovered a new stem cell in the adult brain. These cells can proliferate and form several different cell types -- most importantly, they can form new brain cells. Scientists hope to take advantage of the finding to develop methods to heal and repair disease and injury in the brain. Analyzing brain tissue from biopsies, the researchers for the first time found stem cells located around small blood vessels in the brain. The cell's specific function is still unclear, but its plastic properties suggest great potential. "A similar cell type has been identified in several other organs where it can promote regeneration of muscle, bone, cartilage and adipose tissue," said Patrik Brundin, M.D., Ph.D., Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Research Institute (VARI), Head of the Neuronal Survival Unit at Lund University and senior author of the study. In other organs, researchers have shown clear evidence that these types of cells contribute to repair and wound healing. Scientists suggest that the curative properties may also apply to the brain. The next step is to try to control and enhance stem cell self-healing … Continue reading

Comments Off on New Stem Cell Found in the Brain

New stem cell found in brain: Finding could be key to developing methods to heal and repair brain injury and disease

Posted: Published on April 20th, 2012

ScienceDaily (Apr. 20, 2012) esearchers at Lund University in Sweden have discovered a new stem cell in the adult brain. These cells can proliferate and form several different cell types -- most importantly, they can form new brain cells. Scientists hope to take advantage of the finding to develop methods to heal and repair disease and injury in the brain. Analyzing brain tissue from biopsies, the researchers for the first time found stem cells located around small blood vessels in the brain. The cell's specific function is still unclear, but its plastic properties suggest great potential. "A similar cell type has been identified in several other organs where it can promote regeneration of muscle, bone, cartilage and adipose tissue," said Patrik Brundin, M.D., Ph.D., Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Research Institute (VARI), Head of the Neuronal Survival Unit at Lund University and senior author of the study. In other organs, researchers have shown clear evidence that these types of cells contribute to repair and wound healing. Scientists suggest that the curative properties may also apply to the brain. The next step is to try to control and enhance stem cell self-healing properties with the … Continue reading

Comments Off on New stem cell found in brain: Finding could be key to developing methods to heal and repair brain injury and disease

Nature Publishes Work Utilizing N-Gene's Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy

Posted: Published on April 20th, 2012

NEW YORK, April 19, 2012 /PRNewswire/ --N-Gene Research Laboratories, Inc. ("N-Gene"), today announces that Australian scientists in close cooperation with N-Gene have shown that BGP-15, a heat shock protein inducer, may be a novel therapy for treating the deadly, rare disease, Duchenne Muscular Dystrophy (DMD), as recently reported in the journal Nature. Currently there is no cure and no adequate therapy for DMD. BGP-15 was not only able to make a key protein functional again, thereby reducing muscle damage, but also increase the strength and endurance, and ultimately the lifespan, of DMD animals. "This pioneering work strengthens N-Gene's roleat the forefront of heat shock protein science," said Gabor K. Kalman, chief executive officer of N-Gene. Peter Literati, Ph.D., co-founder and chief scientific officer of N-Gene said, "We believe this publication reinforces the expectation that N-Gene's platform technology, based on stress-response regulation, will eventually result in the emergence of a novel drug class with diverse therapeutic directions. We are remaining focused on advancing BGP-15 for the treatment of type 2 diabetes, but we look forward to seeking partners with which to advance this technology and realize its potential in the treatment of DMD as well as many other disease indications." Dr. … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Nature Publishes Work Utilizing N-Gene's Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy

Page 6,919«..1020..6,9186,9196,9206,921..6,9306,940..»